Top cancer scientists, former NIH leaders, and patient advocates warned that the Trump administration's cuts to science ...

Immunic's MS drug shows 20% risk reduction vs placebo; Entrada cuts jobs; Henlius-Sandoz deal; Cellectar explores options; ...

Novartis to acquire Regulus Therapeutics for $7/share with potential $7 CVR tied to farabursen approval. Deal values Regulus ...

GSK said its decoupling with Haleon is a key reason why it views itself as “well-positioned” in the face of potential ...

BridgeBio's Attruby exceeds Q1 forecasts with $36.7M in sales, 2,072 prescriptions. CEO Neil Kumar credits clinical data; ...

Noma Therapy, a virtual ketamine-assisted therapy provider, has launched with $4.25 million in funding, Endpoints News ...

Pfizer CEO Albert Bourla gave an optimistic read on Tuesday when asked how he thought the trade levies might be implemented.

Live stream podcast tomorrow at 12pm ET with Drew Armstrong, Max Bayer & Anna Brown discussing pharma industry's response to ...

Devoted Health shows growth in 2024 with increased membership and revenue while reducing operating losses, contrasting with ...

Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...

The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the ...

Eli Lilly partners with Creyon Bio in $13M upfront deal, potential $1B+ milestone payments. CEO Serge Messerlian leads ...